Data / Drug companies / Catalent Pharma Solutions, LLC
Catalent Pharma Solutions, LLC: 273 products in the FDA NDC directory, labeler code 11014
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Catalent Pharma Solutions, LLC (labeler code 11014) lists 273 products in the FDA National Drug Code Directory. By type: 273 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on September 11, 2026.
The request: Watch Catalent Pharma Solutions, LLC (FDA labeler code 11014): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 11014
- Products in commercial distribution
- 273
- Packages
- 295
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule II 16, Schedule III 7, Schedule IV 16, Schedule V 3
- Started marketing in the last 12 months
- 7
- Products with a marketing end date set
- 10
- Earliest marketing start
- February 10, 1958
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 240 | 87.9% |
| Export only | 33 | 12.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 273 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 120 | 44% |
| Tablet, film coated | 34 | 12.5% |
| Capsule, liquid filled | 31 | 11.4% |
| Capsule, extended release | 31 | 11.4% |
| Tablet | 19 | 7% |
| Capsule, gelatin coated | 9 | 3.3% |
| Insert | 5 | 1.8% |
| For suspension, extended release | 4 | 1.5% |
| Lozenge | 4 | 1.5% |
| Spray | 4 | 1.5% |
| Powder | 3 | 1.1% |
| Injection, solution | 2 | 0.7% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Apitegromab | 11014-0769 | Injection, solution | Drugs for further processing | September 11, 2026 |
| Lunsotogene parvec | 11014-0768 | Injection, solution | Drugs for further processing | April 23, 2026 |
| Ensitrelvir | 11014-0763 | Tablet | Drugs for further processing | April 16, 2026 |
| Selinexor | 11014-0767 | Tablet, film coated | Drugs for further processing | January 5, 2026 |
| Etripamil | 11014-0766 | Spray | Drugs for further processing | January 5, 2026 |
| Sodium oxybate | 11014-0764 | For suspension, extended release | Drugs for further processing | January 1, 2026 |
| Hydrocortisone | 11014-0765 | Capsule | Export only | December 8, 2025 |
| Levodopa | 11014-0733 | Capsule | Export only | September 30, 2025 |
| Suzetrigine | 11014-0753 | Tablet, film coated | Drugs for further processing | August 18, 2025 |
| Relacorilant | 11014-0734 | Capsule | Drugs for further processing | August 4, 2025 |
| Pralsetinib | 11014-0740 | Capsule | Drugs for further processing | July 30, 2025 |
| Sebetralstat | 11014-0730 | Tablet, film coated | Drugs for further processing | July 4, 2025 |
| Zanubrutinib | 11014-0719 | Tablet, film coated | Drugs for further processing | April 12, 2025 |
| Selinexor | 11014-0729 | Tablet, film coated | Drugs for further processing | March 10, 2025 |
| Crinecerfont | 11014-0681 | Capsule | Drugs for further processing | February 28, 2025 |
| Omega-3-acid ethyl esters | 11014-0710 | Capsule, liquid filled | Drugs for further processing | February 27, 2025 |
| Suzetrigine | 11014-0728 | Tablet, film coated | Drugs for further processing | February 14, 2025 |
| Relacorilant | 11014-0711 | Capsule | Drugs for further processing | February 11, 2025 |
| Nicotine | 11014-0743 | Lozenge | Drugs for further processing | February 3, 2025 |
| Nicotine | 11014-0742 | Lozenge | Drugs for further processing | February 1, 2025 |
| Nicotine | 11014-0745 | Lozenge | Drugs for further processing | January 1, 2025 |
| Nicotine | 11014-0744 | Lozenge | Drugs for further processing | January 1, 2025 |
| Xanomeline and trospium chloride | 11014-0725 | Capsule | Drugs for further processing | December 10, 2024 |
| Xanomeline and trospium chloride | 11014-0724 | Capsule | Drugs for further processing | November 27, 2024 |
| Xanomeline and trospium chloride | 11014-0723 | Capsule | Drugs for further processing | November 22, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.